The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genentech
A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
 
Joseph W. Kim
Consulting or Advisory Role - Dendreon; TRM Oncology; Voluntis
Research Funding - Immune Design
 
David R. Shaffer
Honoraria - Exelixis; Genentech/Roche
Consulting or Advisory Role - Exelixis; Genentech/Roche
Speakers' Bureau - Exelixis
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Genentech/Roche; Ipsen; Janssen; Lilly; Novartis; Orion; Pfizer; Sanofi
 
Thomas Powles
Honoraria - Bristol-Myers Squibb; MERCK; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Ipsen
 
Lauren Christine Harshman
Consulting or Advisory Role - Dendreon; Genentech; KEW; Medivation/Astellas; NCCN; Pfizer; PlatformQ Health; Theragene
Research Funding - Bayer (Inst); Dendreon (Inst); Genentech/Roche (Inst); Medivation/Astellas (Inst); Sotio (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Fadi S. Braiteh
Stock and Other Ownership Interests - Agios; Bristol-Myers Squibb; Clovis Oncology; Insys Therapeutics; Tesaro
Honoraria - Abbott Nutrition; Amgen; ARIAD; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; HERON; Incyte; Insys Therapeutics; Insys Therapeutics; Ipsen; Lexicon; Lilly; Taiho Pharmaceutical
Consulting or Advisory Role - Ambry Genetics; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Incyte; Insys Therapeutics; Ipsen; Ipsen; Lexicon; Lilly; Merck; Merrimack; Pfizer; Regeneron; Sanofi
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Incyte; Insys Therapeutics; Ipsen; Lilly; Merck; Merck; Merrimack; Pfizer; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bayer; Bayer/Onyx; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Exelixis; HERON; Incyte; Insys Therapeutics; Ipsen; Lexicon; Merrimack; Novartis; Pfizer; Regeneron; Roche/Genentech; Sanofi; Taiho Pharmaceutical; Tesaro
 
Paul R. Conkling
Employment - Virginia Oncology Associates
Research Funding - US Oncology; US Oncology (Inst)
 
Indrani Sarkar
Employment - Genentech
 
Edward E. Kadel
Employment - Genentech
Stock and Other Ownership Interests - Genentech/Roche
Travel, Accommodations, Expenses - Genentech
 
Sanjeev Mariathasan
Employment - Genentech
 
Carol O'Hear
No Relationships to Disclose
 
Christina Schiff
Employment - Genentech
Stock and Other Ownership Interests - Genentech/Roche
 
Marcella Fasso
Employment - Roche/Genentech
Stock and Other Ownership Interests - Aduro BioTech; Roche/Genentech
 
Susheela Carroll
Employment - Genentech
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio
Expert Testimony - Celgene; sanofi